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Regulation of Type 1 Iodothyronine 
Deiodinase in Health and Disease
Ronald J. Koenig
The major physiologic function of type 1 iodothyronine deiodinase (D1) is to produce triiodothyronine (T3) for
the plasma. D1 activity is regulated by numerous factors, perhaps the most important of which in human patho-
physiology is T3. T3 induces D1 expression, contributing to the T3 excess commonly found in hyperthyroidism.
Cytokines, nutritional status, sex steroids, and other factors also regulate D1 activity, although different organs
often show different responses. Numerous homeostatic mechanisms can counterbalance isolated changes in D1
expression, such as the genetically decreased expression in C3H/He mice. Two relatively commonly used drugs,
propylthiouracil and amiodarone, inhibit D1, which can have substantial effects on circulating thyroid hormone
levels. Overall, many factors interact in complex ways to establish D1 levels, contributing to the circulating con-
centrations of thyroxine (T4) and T3.
835
Introduction
THE MAJOR PHYSIOLOGIC function of type 1 iodothyroninedeiodinase (D1) is to produce triiodothyronine (T3) for
the plasma. However, other sources (D2 and direct thyroidal
secretion) also contribute to the circulating T3. In humans, it
has not been possible to quantify the percentage of plasma
T3 specifically attributable to D1. D1 is expressed primarily
in the liver, kidney, thyroid and pituitary. It also is expressed
at low levels in numerous other tissues, such as (in the rat)
intestine, placenta, lactating mammary gland and central
nervous system. In contrast to the rat, humans do not ex-
press D1 in the central nervous system.
D1 Ontogeny
D1 expression during ontogeny has been investigated in
several species. Although the developmental patterns of ex-
pression have been described, the mechanisms that control
expression during development remain to be elucidated. In
the developing chick, hepatic D1 activity is low at embryo-
logic day 15 (E15) and gradually increases thereafter until
hatching (1–3). D1 mRNA levels did not show a consistent
pattern in one study (1), so the basis for the increase in D1
activity over time is not clear. It is interesting to note that
plasma T3 levels increase only modestly during the early
stages of the D1 increase, probably due to a simultaneous in-
crease in D3 and/or because of D1-catalyzed inner ring de-
iodination.
In the rat, liver and kidney D1 mRNA and enzyme activ-
ity are low at E19–20 but rise gradually from postnatal day
1 (P1) to P10, increasing further at adulthood (4). The pat-
tern for intestine D1 is similar, except that expression drops
dramatically after P10. Pituitary and thyroid D1 increase
gradually from P12 to adulthood.
In humans, D1 ontogeny has been studied only in liver
(5). Using postmortem tissues from fetuses of 20 weeks’ ges-
tation, preterm infants of 27–32 weeks’ gestation and term
infants who survived up to 39 weeks postnatally, D1 activ-
ity did not show a clear dependence on age. D1 activity in
these postmortem samples was approximately 25% of that
measured in presumably healthy adult transplant donor liv-
ers. The necessity of studying postmortem tissues from sick
fetuses and infants limits the conclusions, but the relatively
prominent fetal hepatic D1 activity contrasts with fetal rat
liver yet is similar to ontogeny in chick liver. Also similar to
the chick, human fetal serum T3 is low despite the clear ex-
pression of D1. These same human fetal livers robustly ex-
pressed D3 (in contrast to adult liver), which presumably
helps prevent the accumulation of circulating T3.
Regulation of D1 by T3
Thyroid hormone induces transcription of the human, rat
and mouse D1 (Dio1) genes (6,7), although this regulation is
not universal because it is absent in the house musk shrew
(8). In humans, therefore, one would expect hyperthyroidism
to induce D1, increasing relative T3 production. Indeed, hy-
perthyroidism is commonly associated with a greater eleva-
tion in T3 than T4, and D1 activity was elevated approximately
threefold in a group of seven Graves’ disease thyroid glands
compared to five normal thyroids (9). Furthermore, plasma
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T3 levels appear to be decreased by the D1 inhibitor propyl-
thiouracil (PTU) more substantially in hyperthyroid patients
than in normal individuals, suggesting that D1 makes a larger
contribution to circulating T3 in hyperthyroidism than in the
euthyroid state (discussed in Bianco et al. [10]).
The human Dio1 promoter contains two functional T3 re-
sponse elements (TREs) (11). The more distal TRE has the
classic structure of an AGGTCA-like direct repeat separated
by a 4-bp spacer. As expected, this TRE binds well to het-
erodimers of retinoid X receptors (RXRs) and T3 receptors
(TRs). The proximal TRE is quite unusual and has the struc-
ture of a direct repeat separated by 10 bp. The binding sites
are octamers (YYRGGTCA) rather than hexamers, and this
TRE binds TR monomers and homodimers, but does not
bind RXR-TR heterodimers. It is the first example of a natu-
rally occurring TRE that appears to function independently
of RXR. Although the rat and mouse Dio1 genes also are in-
duced by T3, the TREs have yet to be identified.
There are two TR genes (Thra and Thrb), and the major
functional receptors derived from these genes are denoted
TR1 and TR1. Liver expresses substantially more TR1
than TR1. As is found for many hepatic proteins, the ex-
pression of TR1 is not uniform, but is zonated. In rodents,
TR1 expression is highest close to the central veins, and D1
expression probably is highest in the same regions (12). T3
induction of hepatic and renal D1 is severely blunted in
TR1-null mice, but is normal in TR1-null mice (13). Mice
that are null for both TRs have no detectable hepatic D1,
demonstrating an ancillary role for TR1 in the regulation of
Dio1 and indicating that TRs (TR1 or TR1) are required for
the basal expression of hepatic D1.
Thyroid D1
In addition to being induced by T3, thyroid gland D1 ac-
tivity is induced by thyrotropin (TSH) (14–16) and cyclic
adenosine monophosphate (cAMP) (17), the major mediator
of TSH signaling. The rat thyroid cell line FRTL5 often is
used as a model system for studying thyrocyte biology. In
FRTL5 cells, TSH and T3 also increased D1 mRNA (17). Sim-
ilar to the effect of TSH, immunoglobulin G from patients
with Graves’ disease induced D1 (18). If this effect occurs in
humans with Graves’ disease, it could contribute to the rel-
atively large elevation in serum T3. The mechanism of the
TSH and cAMP effect is unknown, but it does require new
protein synthesis and is somewhat slower than the response
to T3, suggesting that it may be indirect. The T3 response is
a direct transcriptional effect, although as noted above, TREs
have yet to be identified in the rat and mouse Dio1 genes.
Effects of Drugs on D1 Activity
Two clinically important drugs have substantial effects on
D1 activity. Although propylthiouracil (PTU) is used to treat
hyperthyroidism primarily because it inhibits thyroid per-
oxidase, at high doses PTU also inhibits D1 activity (19). Me-
thimazole does not have a similar effect, making PTU the
preferred drug in thyroid storm. PTU is thought to inhibit
D1 by complexing with the D1 active site selenocysteine via
an S-Se bond (20).
Administration of the antiarrhythmia drug amiodarone
leads to a predictable series of changes in serum thyroid hor-
mone levels (21). Acutely, T3 falls and reverse triiodothyro-
nine (rT3) rises, followed by increases in T4 and TSH. Even-
tually, a new steady state is achieved in which the T4 is in-
creased (sometimes above the assay reference range) and the
TSH and T3 are normal. These changes are at least partially
accounted for by inhibition of D1 activity (22). Despite the
clear-cut in vivo inhibition of D1, it is difficult to demonstrate
inhibition by adding amiodarone to in vitro enzyme assays
(23). In part this may reflect technical difficulties due to the
limited solubility of amiodarone. However, amiodarone de-
rivatives do inhibit D1 activity in vitro (23), suggesting that
the in vivo effects may be caused by amiodarone metabolites.
Inhibition by amiodarone derivatives appears to be compet-
itive with the substrate T4.
The Nonthyroidal Illness Syndrome
The nonthyroidal illness syndrome (NTIS), also known as
the sick euthyroid syndrome or low T3 syndrome, is a com-
plex whole body response to virtually any serious illness
(24). Although the validity of free hormone measurements
in the NTIS has been questioned (25), it is generally felt that
a low circulating free T3 is the hallmark of the syndrome (26).
rT3 is elevated, and the TSH and free T4 usually are normal.
In more severely ill patients the TSH is subnormal, and the
free T4 also can be low in extremely ill individuals. If a pa-
tient overcomes the illness, all of these changes resolve. In
fact, the TSH may transiently rise above the reference range
during the recovery phase. It is commonly speculated that
the NTIS is an evolutionary adaptation to illness, as tissue
hypothyroidism would conserve energy. However, whether
the NTIS remains adaptive in the modern day era of inten-
sive care unit medicine is unclear. Most endocrinologists do
not treat the NTIS, although well-reasoned arguments for
treating the most severe cases have been put forth (27). Clin-
ical studies have failed to demonstrate a benefit to thyroid
hormone therapy in the NTIS (28,29), but the very small
number of patients studied makes it seem unlikely that a true
benefit would have been identified, especially if only certain
subgroups of patients are potential responders.
Many different changes in thyroid hormone economy con-
tribute to the NTIS. That TSH is normal in the setting of a
low free T3 indicates that the hypothalamic-pituitary axis has
an altered response to circulating thyroid hormone. The de-
crease in serum T3 primarily reflects a decrease in periph-
eral deiodination of T4, but as discussed below, the basis for
the decreased T4 to T3 conversion is uncertain and is likely
multifactorial.
Animals models of illness are associated with decreases in
hepatic D1 (30,31). Various cytokines have been adminis-
tered to humans (32) or animals (31) in an attempt to repro-
duce the NTIS. Although changes similar to the NTIS in-
cluding a decreased serum T3 are commonly observed, the
syndrome has yet to be precisely mimicked. Thus, it is felt
that cytokines contribute to the NTIS but cannot fully ex-
plain it, or that the syndrome is mediated by complex cyto-
kine combinations that have yet to be tested experimentally.
Because a decrease in hepatic D1 is clearly associated with
animal models of NTIS, the effects of cytokines on hepato-
cyte D1 have been studied in cell culture. Using the human
hepatoma cell line HepG2, tumor necrosis factor (TNF)-
was observed to inhibit the T3 induction of D1, and this was
mediated by induction of NF-B (33). In principle, such an
effect would decrease T3 production, which would further
reduce the induction of D1 by T3, thus setting off a down-
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ward spiral. Another study, using primary cultures of rat 
hepatocytes, demonstrated that interleukin (IL)-1 and IL-6
block the T3 induction of D1, and that this effect appears to
be mediated by a functional deficiency in a TR coactivator
protein known as steroid receptor coactivator-1 (34).
Interestingly, the effects of cytokines on pituitary D1 ap-
pear to be in the opposite direction (35). In primary cultures
of rat pituitary cells, IL-1 stimulated D1 1.8-fold, and IL-6
and TNF- caused similar changes but they failed to achieve
statistical significance. A single injection of lipopolysaccha-
ride into adult male rats led to a transient 1.5-fold elevation
of anterior pituitary D1, although hepatic D1 decreased as
expected. If similar inductions occur in human pituitary thy-
rotrophs in the NTIS, this could contribute to the failure of
circulating TSH to rise in the face of a low circulating T3 level.
Deiodinase levels also have been studied in one large se-
ries of humans with the NTIS, in which liver and skeletal
muscle biopsies were obtained from more than 50 deceased
patients from the intensive care unit (36). The tissue samples
were obtained on average approximately 20–25 minutes af-
ter death. D2 activity was undetectable in all of the samples.
D1 enzyme activity was detectable in all livers, and D3 was
detectable in many liver and muscle samples (D3 was not
detectable in healthy human liver or skeletal muscle). He-
patic D1 was lowest in patients who died of cardiovascular
collapse, intermediate in patients who died of multiorgan
failure, and highest in patients who died acutely of severe
brain damage (in those patients D1 activity was stated to be
similar to that in normal liver). Although only correlations
can be drawn from this study, it does suggest the potential
for decreased hepatic D1 as a contributing factor to the NTIS.
However, because in humans it has not been possible to
determine the contributions of D1 and D2 to circulating T3,
it is not possible to determine whether inhibition of D1, D2,
or both is most important in the NTIS. In addition, the un-
expected induction of D3 in the above study suggests that
as a possible contributing factor. Further complicating the
situation, there is evidence for decreased T4 uptake into tis-
sues during human fasting (37), which is associated with thy-
roid hormone changes similar to those observed in the NTIS.
Obviously, decreased cellular uptake of T4 also could lead
to decreased T3 production. Thus, additional research is
needed to resolve the mechanism of low T3 in the NTIS, as
well as to address whether the syndrome should ever be
treated (and if so, how).
Mammary Gland D1
Lactation induces deiodinase expression in the mammary
gland, which is speculated to contribute to milk T3 content.
In the rat, D1 is expressed, but in cows and pigs, D2 is ex-
pressed. Rat mammary gland D1 mRNA contains a short-
ened 3 untranslated region (38), but whether this is physi-
ologically significant is unknown. Studies in the rat indicate
that suckling induces mammary gland D1 mRNA and en-
zyme activity through a mechanism involving -adrenergic
stimulation, and that expression is confined to alveolar ep-
ithelial cells (39). Prolactin also increased D1 enzyme activ-
ity, but mRNA levels did not change.
Sex Steroid Regulation of D1
Hepatic D1 mRNA and enzyme activity are higher in
male rats than in female rats, although there are no dif-
ferences in kidney D1 (40,41). Castration reduced hepatic
D1 in male rats and testosterone therapy overcame this re-
duction, both at the mRNA and enzyme activity levels (42).
In one study (42) but not in another (40), ovariectomy of
rats reduced liver D1 activity and this basal level was stim-
ulated by estrogen therapy but reduced further by pro-
gesterone (42). Progesterone also blocked the estrogen in-
duction. The mechanisms involved are unknown. More
modest but qualitatively similar changes were observed in
pituitary D1.
Regulation of Hepatic D1 by Circadian Rhythms and
Feeding Behavior
As noted previously, TR1 and D1 are preferentially ex-
pressed in the pericentral zones in rat liver. TR1 expression
varies in a diurnal manner, with highest expression at the
beginning of the dark period (7:30 PM) and lowest expres-
sion in the middle of the light period (1:30 PM) (12). The max-
imum difference is modest, approximately 30% more TR1
at 7:30 PM, but this might be physiologically relevant as both
D1 and another T3-responsive hepatocyte gene, glutamine
synthase, tended to show a diurnal variation in expression
with peak levels at night.
Liver D1 also is regulated by feeding behavior (43). When
rats are trained to have food access restricted to only 2 or 3
hours per day, they begin to anticipate food availability as
evidenced by increased locomotion and water drinking. In
rats maintained on such a restricted feeding schedule (feed-
ing from 12:00 PM to 2:00 PM daily), D1 activity was low both
before (8:00 AM) and during (11:00 AM) anticipatory activity,
but increased threefold to fourfold after eating (4:00 PM). De-
spite this substantial change in D1 enzyme activity, D1
mRNA was constant. This is different than the well docu-
mented decrease in rat liver D1 associated with fasting in
two ways. Fasting causes a decrease in D1 mRNA as well as
enzyme activity. In addition, the level of D1 activity was ac-
tually lower during anticipatory activity than following a 
24-hour fast in rats otherwise fed ad libitum. As an aside, it
should be noted that the fasted rat is a poor model for fast-
ing humans.
D1 Deficiency
Because the role of D1 is to supply plasma T3, one might
expect D1 deficiency to result in a low T3 concentration.
There are no documented cases of D1 deficiency in humans,
and D1 null animals have not been generated. However,
the mouse strain C3H/He has 5-10 fold reduced D1 ex-
pression relative to most other strains, such as C57BL/6
(44,45). Remarkably, total and free T3 levels are normal in
C3H/He mice. This normal free T3 is generated at the ex-
pense of twice normal circulating free T4 levels, thus illus-
trating the power of thyroid axis homeostasis. Perhaps sur-
prisingly, the normal free T3 and elevated free T4 occur with
no detectable change in circulating TSH. This reequilibrated
state likely is a consequence of several counterbalancing
forces. Assuming mice are similar to rats, then direct thy-
roidal secretion accounts for approximately 40% of circu-
lating T3 (versus 20% in humans), and D1 accounts for ap-
proximately half of the remainder. While the fractional
conversion of T4 to T3 by D1 would be reduced in C3H/He
mice, the higher free T4 level would increase the net flux
through this system. D1 also can degrade T4 via inner ring
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deiodination, and presumably this activity would be de-
creased in C3H mice, helping to maintain the elevated free
T4. The fact that TSH is not decreased in response to the
high free T4/normal free T3 state perhaps reflects decreased
pituitary D2 (T4 stimulates proteosomal degradation of D2),
which would lead to reduced pituitary T3. Overall, these
multiple factors enforce euthyroidism in the C3H/He
mouse. The results suggest that partial D1 deficiency in hu-
mans, should it exist, might be well compensated and dif-
ficult to detect.
The underlying reason for decreased D1 expression in
C3H/He mice has been carefully investigated. The enzyme
itself is normal, but expression at the mRNA and protein lev-
els is reduced. The defect maps to the Dio1 gene itself, and
appears to be accounted for at least in part by a 21 bp in-
sertion in the promoter region that includes five CTG repeats
(46). The 21-bp insertion correlates with decreased promoter
activity, but the mechanism is not known.
D1 Activity and Circulating Thyroid Hormone Levels in
Selenium Deficiency
Because D1 is a selenoprotein, one would predict that se-
lenium deficiency would decrease D1 enzyme activity. In
fact, selenium deficiency in rats was shown to decrease he-
patic and renal D1 activity before the enzyme was cloned
and demonstrated to contain selenocysteine (47–49). How-
ever, organs such as the thyroid and pituitary are much more
resistant to dietary selenium deficiency than is the liver, so
the effects of selenium deprivation depend on the organ be-
ing studied. Selenium deficient rats have an elevated T4, a
very slightly reduced T3 and a normal TSH (47,48). At least
in terms of the T4 and TSH, these findings are similar to what
is observed in the partially D1-deficient C3H/He mouse (44).
However, it should be recognized that selenium deficiency
could influence thyroid hormone levels by mechanisms in-
dependent of D1. For example, selenium deficiency could
impair D2 or D3 activity. In addition, even though the thy-
roid is relatively resistant to selenium deficiency, decreased
activity of the selenoenzyme glutathione peroxidase in the
thyroid might increase peroxide levels, which could enhance
iodine organification in the short term or be cytotoxic in the
long term.
In humans, it would be difficult to find cases of pure, iso-
lated selenium deficiency. Nevertheless, selenium deficient
humans tend to have mildly elevated serum T4 levels (50–53).
Interestingly, in an area of Zaire with both iodine and sele-
nium deficiency, selenium supplementation was associated
with a decrease in serum T4 and, in subjects with cretinism,
an elevation in TSH (i.e., worsening hypothyroidism) [54,55].
One possible explanation is that selenium deficiency reduced
D1-catalyzed inner ring deiodination of thyroid hormones,
thus protecting against hypothyroidism.
D1 Activity in Diabetes Mellitus
Experimental diabetes mellitus in rats caused a 50%–60%
decrease in hepatic and kidney D1, as well as decreases in
serum T3 and T4 (56). Insulin treatment resulted in a slow
increase in D1 mRNA, with an increase first noted at 72 hours
and normalization after 1 week. In contrast, glucagon ad-
ministration appears to reduce D1 activity (57).
D1 in Pituitary Tumors
Because D1 is expressed in the normal anterior pituitary,
it might be anticipated that human pituitary tumors also
could express this enzyme. One study has reported the mea-
surement of deiodinase activity in 43 pituitary adenomas and
three normal pituitaries, all removed surgically (58). The ade-
nomas included 18 nonfunctioning tumors, 7 TSH-secreting
tumors, 5 growth hormone (GH) secreting tumors, 1 com-
bined TSH and GH-secreting tumor, 8 prolactinomas and 4
adrenocorticotropic hormone (ACTH)-secreting tumors. Al-
though there was a large variation in D1 activity within tu-
mor types, the highest activities were seen in the thyrotroph
and lactotroph adenomas. Approximately half of these tu-
mors had D1 activities several-fold greater than any of the
three normal pituitaries. Many of the tumors also expressed
D2.
Summary and Conclusions
Type 1 deiodinase activates thyroxine via outer ring de-
iodination and also has the ability to inactivate thyroid hor-
mone via inner ring deiodination. Thus, D1 makes an im-
portant contribution to the maintenance of circulating thy-
roid hormone levels. Although the percent of plasma T3 that
is caused by D1 activity has been quantified in the rat, it has
been difficult to make a similar determination in humans.
D1 expression is highest in the liver, kidney, thyroid and pi-
tuitary, and it also is expressed at low levels in several other
organs. T3 induces D1 expression at the transcriptional level,
which contributes to the relative excess of T3 in hyperthy-
roidism. Amiodarone (or its metabolites) inhibits D1 activ-
ity, potentially creating difficulty in the interpretation of thy-
roid function tests. The ability of PTU to inhibit D1 is
advantageous in the treatment of severe hyperthyroidism.
D1 activity is low in the nonthyroidal illness syndrome,
where this may contribute to the low T3 state. D1 activity in
other organs, such as the lactating mammary gland, may be
physiologically important, although further research is
needed to better define the roles of D1 in human health and
disease.
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